GlassScriptPhysician profile
Judit Gellen
NPI 1407817406
$10,858.06
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,418 · 2020: $4,572 · 2021: $2,463 · 2022: $1,238 · 2023: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Athenex Pharmaceutical Division, LLC | $3,850.00 | 2020 | |
| Celgene Corporation | $1,835.94 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $1,633.57 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $612.20 | 2019-2022 | |
| Pfizer INC. | $424.28 | 2019-2022 | |
| Amgen INC. | $286.24 | 2019-2022 | |
| Janssen Biotech, INC. | $265.90 | 2019-2022 | |
| Astellas Pharma US INC | $254.35 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $160.92 | 2019-2021 | |
| Seagen INC. | $149.32 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $147.57 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $115.95 | 2020-2022 | |
| Aveo Pharmaceuticals, INC. | $114.32 | 2022 | |
| Comsort, INC | $100.00 | 2019 | |
| Array Biopharma INC | $93.11 | 2020-2022 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $75.07 | 2020-2021 | |
| Emd Serono, INC. | $71.88 | 2019-2021 | |
| Pharmacyclics LLC, An Abbvie Company | $65.00 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.89 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $58.42 | 2021-2022 | |
| Beigene USA, INC. | $53.08 | 2020-2021 | |
| Abbvie INC. | $43.93 | 2020-2022 | |
| Myovant Sciences INC. | $41.25 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $39.91 | 2021 | |
| Lilly USA, LLC | $31.93 | 2020-2022 | |
| Daiichi Sankyo INC. | $29.52 | 2020-2021 | |
| Genzyme Corporation | $21.46 | 2022 | |
| Incyte Corporation | $20.83 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $19.98 | 2022 | |
| Tactile Systems Technology INC | $19.59 | 2022 | |
| Kyowa Kirin, INC. | $19.43 | 2019 | |
| Epizyme, INC. | $19.23 | 2021 | |
| Glaxosmithkline, LLC. | $17.25 | 2021 | |
| Stemline Therapeutics INC. | $16.75 | 2019 | |
| Exelixis INC. | $16.37 | 2020 | |
| Puma Biotechnology, INC. | $16.24 | 2020 | |
| Morphosys, US INC. | $16.19 | 2022 | |
| Agios Pharmaceuticals, INC. | $16.06 | 2022 | |
| Genentech USA, INC. | $12.98 | 2019 | |
| Alexion Pharmaceuticals, INC. | $12.15 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judit Gellen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.